Diex Recherche Quebec

Québec G1V 4T3

4 studies enrolling now · 12 studies all time

What they study most

Active Nonsegmental Vitiligo, Cardiovascular Disease, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypertension, Lower Respiratory Tract Illness, Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight, Stable Nonsegmental Vitiligo, Type 2 Diabetes, Type 2 Diabetes Mellitus

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Recruiting now
• REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor — Completed
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before — Completed
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) — Completed
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes — Withdrawn before enrolling